ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Post protocol residual thickness as a negative predictor for pharmacological treatment in early pregnancy loss.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the rate of pharmacological treatment failure in early pregnancy loss, assess post-treatment residua thickness as a predictor of retained products of conception (RPOC), identify a clinically relevant cutoff, and evaluate additional clinical and sonographic predictors.
methodsThis retrospective cohort study was conducted at a tertiary medical center and included patients treated with mifepristone-misoprostol for first-trimester pregnancy loss between January 2019 and January 2022. Treatment success was assessed via transvaginal ultrasound, with residua thickness measured 14 days post-treatment. The primary outcome was failure, defined as histologically confirmed RPOC following hysteroscopy. Secondary analyses evaluated clinical and sonographic predictors, focusing on post-treatment residual thickness. Statistical analysis included receiver operating characteristic (ROC) curve assessment and multivariable logistic regression.
resultsOf the 717 patients included, 537 (74.9%) achieved successful medical management without further intervention, while 180 (25.1%) required intervention. Treatment failure was associated with greater post-treatment residua thickness (mean 19.1 ± 9.1 mm vs. 10.4 ± 6.7 mm, P < 0.001). Residua thickness was an independent predictor of failure (adjusted odds ratio [aOR] 1.17, 95% confidence interval [CI]: 1.13-1.21, P < 0.001). ROC analysis identified an optimal cutoff of 14.9 mm, yielding 70% sensitivity and 81% specificity (area under the curve [AUC]: 0.835, 95% CI: 0.80-0.87) for predicting the need for surgical intervention.
conclusionPost-treatment residual thickness is a significant predictor of pharmacological treatment failure in early pregnancy loss, with a clinically relevant cutoff of approximately 15 mm. Histologic validation provides a promising framework for refining management protocols, emphasizing the need for further studies to establish robust predictive criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.